Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...
Approximately one in seven couples face difficulties conceiving a child naturally. Half of these cases are due to male infertility—either caused by the complete absence or low number of mature sperm.
Opportunities in the North America molecular diagnostics market include rising demand due to increased chronic and infectious diseases, advances in point-of-care testing, and next-generation ...
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN) (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (SOPH) (Nasdaq ...
Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...
The Southern blot, which detects specific DNA sequences, was one of the first molecular diagnostic methods to be widely adopted. 2 This type of probe-based assay uses a single-stranded oligonucleotide ...
Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it ...
Discover how saliva testing detects oral and systemic diseases early. Learn about the mouth-body connection and the power of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results